CA 19-9 Antikörper

Produktnummer ABIN6296794

Dieses Maus Monoklonal-Antikörper erkennt spezifisch CA 19-9 in IHC, FACS und IF. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für CA 19-9 Antikörper (ABIN6296794)

Target: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CA 19-9 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunofluorescence (IF)

Produktdetails anti-CA 19-9 Antikörper

Verwendungszweck: Mouse anti-Human CA19-9 Antibody [Sodium Azide Free]

Spezifität: Cytoplasmic

Aufreinigung: Precipitin lines obtained after immuno-diffusion using mAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as the immunogen for the CA19-9 antibody.

Immunogen: Precipitin lines obtained after immuno-diffusion using mAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as the immunogen for the CA19-9 antibody.

Anwendungsinformationen

Applikationshinweise: Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
Immunofluorescence: 0.5-1 μg/mL
Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1)
Prediluted format: incubate for 30 min at RT (2)

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: In 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.

Details zu CA 19-9

Target: CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))

Andere Bezeichnung: CA19-9

Hintergrund:

Target Description: CA19-9, a carbohydrate epitope expressed on a high MW (>400 kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This mAb is excellent for staining of formalin-fixed, paraffin-embedded tissues.